-
Celator Pharmaceuticals (CPXX) Sees Second Day of Big Gains
-
UPDATE: Roth Sees Celator Pharma's (CPXX) Vyxeos Easily Supplementing Standard of Care 7+3 Therapy; Affirms at 'Buy'
-
CelatorĀ® Pharmaceuticals Closes $43.7 Million Underwritten Financing
-
Celator Pharmaceuticals (CPXX) Prices 4M Common Stock Offering at $9.50/Share
-
CelatorĀ® Pharmaceuticals Announces Pricing Of A $38.0 Million Public Offering Of Common Stock
-
Celator Pharmaceuticals (CPXX) Plans Common Stock Offering
-
CelatorĀ® Pharmaceuticals Announces Proposed Public Offering Of Common Stock
-
NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'
-
Roth Boosts PT on Celator Pharma (CPXX) to $22 Following Vyxeos Phase III Data in High-Risk sAML
-
Roth Capital Raises Price Target to $18 on Celator Pharmaceuticals (CPXX) Seeing Share Price Disconnect
-
Celator's (CPXX) CPX-351 Has Room to Grow in AML Space; Roth Capital Affirms at 'Buy'
-
Celator Pharmaceuticals (CPXX) Phase III Induction CR/CRi Data 'Major Catalyst', Roth Capital Says
-
Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock
-
Unusual 11 Mid-Day Movers 10/20: (SCOK) (ESI) (SHOR) Higher; (IBIO) (NCR) (CPXX) Lower
-
Celator Pharmaceuticals (CPXX) Plans Common Stock, Warrants Offering
-
Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock

